Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients

Katherine Ngo; Dipak Kotecha; Julia Ae Walters; Luis Manzano; Alberto Palazzuoli; Dirk J van Veldhuisen; Marcus Flather

doi:10.1002/14651858.CD007613.pub2

Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients

Katherine Ngo
, Dipak Kotecha
, Julia Ae Walters
, Luis Manzano
, Alberto Palazzuoli
, Dirk J van Veldhuisen
, Marcus Flather

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Abstract

Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in CHF remains unclear.

Original language	English
Pages (from-to)	CD007613
Journal	Cochrane Database of Systematic Reviews
Issue number	1
DOIs	https://doi.org/10.1002/14651858.CD007613.pub2
Publication status	Published - 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Anemia
Heart Failure
Hematinics
Humans
Randomized Controlled Trials as Topic

Access to Document

10.1002/14651858.CD007613.pub2

Cite this

@article{ad46ad32f439427f81158026d2280176,

title = "Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients",

abstract = "Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55\%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in CHF remains unclear.",

keywords = "Anemia, Heart Failure, Hematinics, Humans, Randomized Controlled Trials as Topic",

author = "Katherine Ngo and Dipak Kotecha and Walters, \{Julia Ae\} and Luis Manzano and Alberto Palazzuoli and \{van Veldhuisen\}, \{Dirk J\} and Marcus Flather",

year = "2010",

doi = "10.1002/14651858.CD007613.pub2",

language = "English",

pages = "CD007613",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "Wiley",

number = "1",

}

TY - JOUR

T1 - Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients

AU - Ngo, Katherine

AU - Kotecha, Dipak

AU - Walters, Julia Ae

AU - Manzano, Luis

AU - Palazzuoli, Alberto

AU - van Veldhuisen, Dirk J

AU - Flather, Marcus

PY - 2010

Y1 - 2010

N2 - Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in CHF remains unclear.

AB - Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in CHF remains unclear.

KW - Anemia

KW - Heart Failure

KW - Hematinics

KW - Humans

KW - Randomized Controlled Trials as Topic

U2 - 10.1002/14651858.CD007613.pub2

DO - 10.1002/14651858.CD007613.pub2

M3 - Article

C2 - 20091643

SN - 1465-1858

SP - CD007613

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 1

ER -